Key result
Anakinra successfully treated an adolescent with steroid-dependent idiopathic recurrent pericarditis, serving as an effective, rapidly acting, and steroid-sparing agent.
Why the study?
Children with chronic relapsing idiopathic recurrent pericarditis can develop dependence and side effects from prolonged high-dose corticosteroid regimens, with anakinra emerging as a promising strategy.
Does anakinra improve outcomes in an adolescent with steroid-dependent idiopathic recurrent pericarditis?
Case Report (n=1)
Does anakinra improve outcomes in an adolescent with steroid-dependent idiopathic recurrent pericarditis?
Anakinra appears to be an effective and safe steroid-sparing rescue therapy for children with steroid-dependent idiopathic recurrent pericarditis.
May support anakinra as steroid-sparing rescue in adolescent recurrent pericarditis; hypothesis-generating case report requiring prospective trials.
In approximately 5% of patients with idiopathic recurrent pericarditis, the disease usually follows a chronic relapsing course, and children can develop dependence and side effects of prolonged high-dose corticosteroid regimens. In this setting anakinra, a recombinant human interleukin-1 competitive receptor antagonist that blocks the biologic effects of interleukin-1, thereby reducing systemic inflammatory responses, appears to be one of the most promising strategies. We report an adolescent with steroid-dependent idiopathic recurrent pericarditis that was successfully treated with anakinra, highlighting that this therapeutic option seems to be an effective, rapidly acting, steroid-sparing, and relatively safe agent for the treatment of this entity in children.
No takes yet. Share an insight, caveat, or question.
Rodríguez‐González et al. (2018) conducted a case report in steroid-dependent idiopathic recurrent pericarditis (n=1). Anakinra was evaluated on treatment success. Anakinra successfully treated an adolescent with steroid-dependent idiopathic recurrent pericarditis, serving as an effective, rapidly acting, and steroid-sparing agent.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: